Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.

[1]  U. Capitanio,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. , 2022, European urology.

[2]  E. Philip,et al.  Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review , 2021 .

[3]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[4]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[5]  E. Arias,et al.  United States Life Tables, 2018. , 2020, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[6]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial , 2020, ESMO Open.

[7]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[8]  C. Kong,et al.  Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US , 2020, JAMA network open.

[9]  Liangfang Shen,et al.  Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal-cell carcinoma in the United States. , 2020, The oncologist.

[10]  M. Atkins,et al.  Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. , 2020, Immunotherapy.

[11]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial , 2019, The oncologist.

[12]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[13]  Q. Zhang,et al.  Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma , 2018, Journal of Immunotherapy for Cancer.

[14]  K. Claxton,et al.  Discounting in Economic Evaluations , 2018, PharmacoEconomics.

[15]  M. Hoyle,et al.  Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England , 2018, PharmacoEconomics.

[16]  Abe Dunn,et al.  Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States , 2018, Health services research.

[17]  M. Leshno,et al.  Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. , 2017, European urology.

[18]  Liubao Peng,et al.  Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and Chinese perspectives , 2017, Cancer.

[19]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Culyer,et al.  The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[22]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[23]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[24]  C. Mullins,et al.  Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? , 2014, Journal of managed care & specialty pharmacy.

[25]  Á. Benedict,et al.  Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population , 2013, ClinicoEconomics and outcomes research : CEOR.

[26]  Yuting Zhang,et al.  Comparing local and regional variation in health care spending. , 2012, The New England journal of medicine.

[27]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[29]  J. Angers,et al.  The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data , 1998, PharmacoEconomics.

[30]  W. Henley,et al.  Improved curve fits to summary survival data: application to economic evaluation of health technologies , 2011, BMC Medical Research Methodology.

[31]  Stephen M Roberts,et al.  Body Weight Distributions for Risk Assessment , 2007, Risk analysis : an official publication of the Society for Risk Analysis.

[32]  D. Posada,et al.  Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. , 2004, Systematic biology.